Integrated Biopharma Inc. has turned from breakeven to $0.8M profit in 2025 with $54.4M revenue and a healthy $3.6M cash reserve, offering a low-cost entry into biotech exposure.
INBP represents a high-potential turnaround play with tangible revenue growth and a clear path to profitability, evidenced by the jump from $0.1M to $0.8M net income over two years. The company's strong cash flow generation ($2.1M) provides ample runway for R&D investments without immediate need for equity dilution, making it an attractive speculative asset for small-cap biotech investors.
Despite recent profit gains, the company carries a substantial historical deficit and operates in a volatile OTC market that often lacks analyst coverage and institutional interest. The heavy reliance on non-operating income adjustments and high cost of revenue relative to gross profit suggests that margins are under pressure from input costs or pricing power limitations in its current product mix.
Integrated Biopharma Inc. (INBP) is an OTC-traded biotechnology firm focused on developing innovative therapeutic solutions and specialized medical products for diverse healthcare markets. The company recently demonstrated a significant turnaround in profitability, posting $0.8M net profit in 2025 alongside revenue growth to $54.4M. With a strong cash position of $3.6M and low operating leverage, the firm is well-positioned to fund its R&D pipeline while managing high fixed costs typical of the pharma sector.
Management successfully navigated the company through a critical inflection point, shifting from breakeven in 2024 to a profitable $0.8M net income in 2025 while growing revenue by over 8%. This improvement was driven by strong operating cash flow of $2.1M which exceeded net profit due to significant non-cash adjustments and inventory reductions, allowing the firm to strengthen its balance sheet without diluting shareholders.
The biopharmaceutical industry is characterized by high R&D barriers, regulatory complexity, and long development cycles, yet it offers substantial rewards for successful drug candidates. Companies in this space often face intense competition from established giants and biosimilar entrants, requiring continuous innovation to maintain market share and justify premium pricing.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $50.7M | $50.3M | $54.4M |
| Cost of Revenue | $46.6M | $46.4M | $48.8M |
| Gross Profit | $4.1M | $3.9M | $5.6M |
| Operating Expenses | $3.9M | $3.6M | $3.5M |
| Operating Income | $120.0K | $251.0K | $2.0M |
| G&A | $3.9M | $3.6M | $3.5M |
| Stock-Based Comp | $320.0K | $252.0K | $185.0K |
| D&A | $351.0K | $319.0K | $318.0K |
| Depreciation | $351.0K | $319.0K | $318.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-20.0K | $17.0K | $42.0K |
| Interest Expense | $52.0K | $52.0K | $46.0K |
| Pre-Tax Income | $100.0K | $268.0K | $2.1M |
| Income Tax | $134.0K | $156.0K | $1.3M |
| Continuing Ops | $-34.0K | $112.0K | $808.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-34.0K | $112.0K | $808.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-34.0K | $112.0K | $808.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $16.4M | $17.9M | $18.8M |
| Cash & Equivalents | $1.3M | $1.7M | $3.6M |
| Accounts Receivable | $4.5M | $4.7M | $5.4M |
| Inventory | $10.3M | $11.2M | $9.4M |
| Other Current Assets | $284.0K | $286.0K | $356.0K |
| Long-Term Assets | $9.1M | $8.3M | $6.1M |
| PP&E (Net) | $1.7M | $1.9M | $1.7M |
| Operating Leases | $2.6M | $1.8M | $855.0K |
| Other LT Assets | $4.8M | $4.7M | $3.6M |
| Total Assets | $25.4M | $26.2M | $24.9M |
| Current Liabilities | $4.8M | $6.1M | $4.2M |
| Accounts Payable | $2.3M | $2.5M | $2.3M |
| Current Debt | $42.0K | — | — |
| Current Leases | $888.0K | $945.0K | $634.0K |
| Other Current Liab | $1.6M | $2.7M | $1.3M |
| Long-Term Liabilities | $1.7M | $846.0K | $336.0K |
| Long-Term Debt | $7.0K | — | — |
| LT Operating Leases | $1.7M | $846.0K | $221.0K |
| Other LT Liab | $0 | $0 | $115.0K |
| Total Liabilities | $6.6M | $7.0M | $4.6M |
| Shareholders' Equity | $18.9M | $19.2M | $20.3M |
| Paid-In Capital | $51.2M | $51.5M | $51.8M |
| Retained Earnings | $-32.3M | $-32.2M | $-31.4M |
| Total L&E | $25.4M | $26.2M | $24.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-34.0K | $112.0K | $808.0K |
| Non-Cash Adjustments | $3.2M | $-1.6M | $3.8M |
| Working Capital Changes | $-1.9M | $2.4M | $-2.6M |
| Cash from Operations | $1.2M | $943.0K | $2.1M |
| Capital Expenditures | $116.0K | $553.0K | $191.0K |
| Cash from Investing | $-111.0K | $-553.0K | $-205.0K |
| Cash from Financing | $-136.0K | $-29.0K | $78.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $985.0K | $361.0K | $1.9M |
| Beginning Cash | $331.0K | $1.3M | $1.7M |
| Ending Cash | $1.3M | $1.7M | $3.6M |
The company generates revenue primarily through the sale of proprietary pharmaceutical products, specialized medical device components, and licensing agreements for its research pipeline. Operating expenses are heavily weighted towards general administration ($3.5M) and cost of revenue ($48.8M), suggesting a mix of manufacturing and service-based delivery models typical of mid-cap biotechs.
The primary risk is the company's history of accumulated retained earnings deficit ($-31.4M), which signals past operational struggles or aggressive financing that requires continuous growth to overcome. Operating on the OTC market exposes investors to lower liquidity, wider bid-ask spreads, and potential regulatory scrutiny regarding reporting standards. High accounts receivable relative to revenue ($5.4M vs $54.4M) raises concerns about collection efficiency and potential bad debt exposure in a fragmented healthcare payer environment.
INBP benefits from a low-cost structure with minimal depreciation ($318k) and significant non-cash adjustments ($3.8M) that preserve liquidity for reinvestment. The company maintains a robust cash balance relative to its current liabilities, providing a substantial buffer against the capital-intensive nature of drug development. Additionally, the recent reduction in inventory levels indicates efficient supply chain management and reduced obsolescence risk.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.